Now, but not yet : tension in obstetrics by Hall, David
INAUGURAL ADDRESS:  PROF DAVID HALL  JUNE 2010
NOW, BUT NOT YET –
TENSION IN OBSTETRICS

David Hall
June 2010
Now, but not yet – tension in obstetrics
Inaugural lecture delivered 17 June 2010
Prof D Hall
Obstetrics and Gynaecology
Faculty of Health Sciences
Editor: SU Language Centre
Design: Heloïse Davis
Printing: rsamprinters@gmail.com
ISBN: 978-0-7972-1329-6
Copyright ©Stellenbosch University Language Centre
avid Hall was born in Harare, Zimbabwe, where he began his schooling.
He subsequently moved to Durbanville, Cape Town, where he con -
cluded his schooling at Durbanville High School. He completed all his
university studies at Stellenbosch University (SU).
After obtaining his MB,ChB degree in 1983, he continued with his studies,
specialising in obstetrics and gynaecology (O&G) and staying on as a con -
sultant in the department. He completed his doctorate in 1999 and was
appointed associate professor in the same department in 2002.
Although registered as a sub-specialist in maternal-fetal medicine, he has a
wide interest across the spectrum of O&G as well as the related fields of
education and ethics. He has served as coordinating assessor of all maternal
deaths in the Western Cape since 1999. His doctoral research was per -
formed on early severe pre-eclampsia and this topic, together with preterm
labour, has been his chief interest of research. Apart from his own local research, he is currently
collaborating on a number of international research projects in obstetric medicine.
David is an active teacher at all levels. He places great emphasis on understanding the adult
learner and enjoys the dual role of teacher and clinician. He has successfully integrated an elec -
tronic resource base into under- and postgraduate lectures. In 2009, he received the Rector’s
Award for Excellence in Education.
David heads the Obstetric Special Care Unit and acted as national chairperson of the Maternal
and Fetal Society of South Africa from January to June 2009. Having registered the sub-specialist
course at SU and the Tygerberg Academic Hospital, he is looking forward to training many success -
ful fellows in maternal fetal medicine.
ACKNOWLEDGEMENTS
At this inaugural lecture, the author would like to thank his parents, wife
and children, university, mentors, colleagues and friends for their significant
support during his studies, research and clinical career.
INTRODUCTION
For most couples, pregnancy is an eagerly anticipatedcondition. Under normal circumstances, pregnancy
begins with conception and, after a period of approxi -
mately 9 months (40 weeks), ends with the spontaneous
delivery of a healthy baby to a healthy mother.
Pregnancy is also, however, a condition that, under
certain circumstances, places the mother at conside ra -
ble risk. Physiological maternal adaptations to preg -
nancy, such as increased plasma volume and cardiac out -
put, insulin resistance and hypercoagulability, may also
increase the risk of complications in the presence of
tissue damage or organ pathology. These changes on
the maternal side may be paralleled on the fetal side
with the fetus and the placenta able to cause patho -
logical changes in pregnancy. It is therefore not uncom -
mon for an essentially normal pregnancy to develop
complications that cause or necessitate delivery remote
from term. When an unexpectedly early, urgent deli -
very becomes imminent, the distant, rosy future is
propelled into an immediate, uncertain present and the
‘not yet’ becomes the ‘now’. Two such dangerous com -
plica tions of pregnancy are pre-eclampsia and preterm
labour.
PRE-ECLAMPSIA
Context
Pre-eclampsia is a multi-system, hypertensive disorder
affecting 2% to 8% of pregnancies.1 This condition de -
velops in the latter half of pregnancy and has a multi-
factorial aetiology that is still only partially understood.
When simplified to its clinical essence, pre-eclampsia
presents as a constellation of symptoms and signs in the
form of a maternal and/or fetal syndrome.2 The chief
characteristics of the maternal syndrome are hyper -
tension and proteinuria. Despite advances in obstetric
and neonatal care, pre-eclampsia and its related com -
plications remain a leading cause of maternal and
perinatal mortality in both developed and developing
countries.3,4 In addition, the condition has a profound
influence on maternal and perinatal morbidity.5,6 In this
context, it is a common referral indication to secondary
and tertiary hospitals.
Pre-eclampsia is classified as one of the hypertensive
diseases of pregnancy. Once the clinician has diagnosed
and classified the condition, it is graded into mild and
severe forms. Classification and grading help to direct
management and to determine prognosis. In addition,
certain investigators believe it important to sub-classify
pre-eclampsia further into early and late disease, as
early disease, defined as the onset of disease at less than
34 weeks’ gestation, is almost always severe.7 The para -
dox of pre-eclampsia is that this potentially life-threate -
ning disease usually reverses completely with the deli -
very of the placenta and, of necessity, the baby.
Upon first consideration, when faced with a preg -
nancy complication that potentially places the lives of
the mother and the baby in danger and that is re versible
following birth, prompt delivery seems to con stitute a
prudent course of action. However, while early delivery
is always in the medical interests of the mother, this is
not necessarily so for the baby, as delivery at an ex -
tremely early gestational age is fraught with compli -
cations. Extreme preterm delivery is associated with
high perinatal mortality and significant morbidity in the
form of lifelong handicap.8 Furthermore, the situation in
all academic hospitals in South Africa is currently com -
plicated by a chronic shortage of the neonatal intensive-
care unit beds needed to care for such babies. Taking
these facts into consideration, two clinical investigators
pioneered a daring alternative.
Expectant management of early 
severe pre-eclampsia
In 1990, Odendaal et al. from the Stellenbosch/
Tygerberg unit published a paper on the expectant ver -
sus aggressive management of early severe pre-
eclampsia.9 Four years later, this small study was
followed by a slightly larger one from the USA.10 The
goal of these studies was to delay the delivery of
mothers with early-onset severe pre-eclampsia to gain
time to improve the perinatal outcome. In both trials,
carefully selected patients were stabilised and managed
by specific doctors in a tertiary institution. Both studies
showed improved perinatal outcomes but, due to the
small numbers involved, a larger study was necessary
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6both to confirm the perinatal gain and to document the
infrequent adverse maternal outcomes more carefully.
For this reason, a prospective case series over 
5 years involving 340 patients with early-onset severe
pre-eclampsia was conducted. This study, which is
current ly the largest prospective case series in patients
with this pregnancy complication, showed that an
average of 11 days was gained before delivery became
necessary for clearly defined maternal and/or fetal indi -
cations. An interesting finding was that more time was
gained for earlier gestations (Figure 1). This time period
enabled fetal-organ maturation to improve, thereby
decreasing the need for neonatal intensive-care unit
admission and resulting in low perinatal mortality rates
at early gestational ages. On the maternal side, 27% of
the women experienced a major maternal com plication
but, because complications were identified early and
treated promptly, few women had poor out comes
(Table 1). There were only three admissions (0.08%) to
the adult intensive-care unit and the average
postpartum stay was not extended beyond that asso -
ciated with delivery by Caesarean section. The authors
concluded that, under carefully controlled circum stan -
ces in selected patients, the expectant management of
early-onset pre-eclampsia is sufficiently safe for the
mother with important perinatal benefits.11,12
Figure 1: Expectant management of early severe 
pre-eclampsia: median number of days gained at each
entry gestation
Table 1: Expectant management of early severe 
pre-eclampsia: maternal complications
HELLP = haemolysis, elevated liver enzymes and low-platelets
syndrome; some patients experienced > 1 complication.
Following the publication of this large prospective case
series, a similar but smaller study was performed in
Paris, France, showing this approach to be beneficial,
even in well-funded circumstances.13
The current situation is that the expectant manage -
ment of early-onset pre-eclampsia is now much more
widely advocated in both developed and developing
countries.14 However, it must be emphasised that this
approach is advised only for carefully selected patients
managed by experienced clinicians, usually in tertiary
institutions.
An important clinical research question that arose
from the above-mentioned studies was “How many
women with early-onset severe pre-eclampsia actually
qualify for expectant management?” The answer was
provided by a subsequent prospective case series per -
formed at the Stellenbosch/Tygerberg unit, which
showed that almost half (48.5%) of the cases admitted
qualified for this approach.5 The reasons preventing the
expectant management of early-onset severe pre-
eclampsia are shown in Table 2.
D
ay
s
Gestation in weeks
Complication No. %
Placental abruption 69 20.2
Ascites 37 10.9
HELLP syndrome 18 5.2
Loss of blood-pressure control 18 5.3
Pulmonary oedema 7 2.1
Severe renal impairment 6 1.7
Eclampsia 4 1.2
Intensive-care unit admission 3 0.8
Death 0
Patients with major comp. 92 27
7Pre-eclampsia: other developments
The Stellenbosch/Tygerberg unit is currently colla -
borating with the University of British Columbia to
develop a scoring system using simple clinical and bio -
chemical markers to predict severe maternal morbidity
within 48 hours of admission.15 Some other important
contributions from the Stellenbosch/Tyger berg unit to
understanding pre-eclampsia have been the investi -
gation of the role of the maternal immune com ponent
in the aetiology of pre-eclamp sia16 and, based on the
same principles, the influence of HIV on the develop -
ment of pre-eclampsia.17 At the level of histopathology,
placentas from cases of early and late-onset pre-
eclampsia have been carefully examined and compared
with controls.18 This was done to seek further evidence
to support the distinction of early from late-onset pre-
eclampsia. Finally, in contrast to early-onset pre-
eclampsia, late-onset pre-eclampsia has been inves -
tigated less and is generally regarded to be mild/mode -
rate disease. However, a careful analysis of cases of late-
onset pre-eclampsia at the Tygerberg and Paarl hos -
pitals has revealed that this condition is often
complicated by the potentially dangerous condition of
eclampsia (13%).19
PRETERM LABOUR
Preterm labour is defined as the onset of true labourbetween a considered point of viability and 36 com -
pleted weeks of pregnancy. The condition is further
func tionally sub-classified as early preterm labour occur -
ring before 34 weeks’ gestation and late preterm labour
occurring from 34 to 36 weeks’ gestation. Second-
trimester pregnancy loss and preterm delivery may be
considered as elements of an obstetrical syndrome with
a multi-factorial aetiology. In this sense, preterm labour
presents the same dilemmas as pre-eclampsia and the
hypertensive conditions of pregnancy. As mentioned
pre viously, early preterm birth has significant conse -
quences for the newborn baby that specifically revolve
around the complications of severe prematurity. How -
ever, unlike pre-eclampsia, preterm labour followed by
the birth of a severely premature baby often occurs
without the mother and/or the baby being medically
‘sick’.
n (%)
Viable fetus 69 (79.3)
Early fetal distress 28 (32.2)
Major maternal complication(s) present 24 (27.6)
34 weeks’ gestation after stabilisation period 8 (9.2)
Major maternal complication + fetal distress 7 (8)
Intra-uterine death 2 (2.3)
Pre-viable fetus 18 (20.7)
Termination of pregnancy < 24 weeks 5 (5.7)
Intra-uterine death 5 (5.7)
Termination of pregnancy for absent or reversed end-diastolic flow 3 (3.4)
Major maternal complication + absent or reversed end-diastolic flow 2 (2.3)
Major maternal complication + termination < 24 weeks 2 (2.3)
Major maternal complication + pre-viable fetus 1 (1.1)
Total 87 (100)
Table 2: Early severe pre-eclampsia: reasons preventing expectant management
Context
Approximately 13 million preterm babies were born
worldwide in 2005. Of these, 85% (11 million) were
born in Africa and Asia, with Africa having the highest
rate of preterm birth (12%). Even in regions where
good-quality care is easily accessible, the rate of pre -
term birth has risen in recent times. In the USA, for
example, there has been a 35% increase in the last 25
years.20 One of the iatrogenic factors leading to this
recent increase is the greater accessibility of assisted
reproduction, resulting in multiple pregnancies, but this
is seldom a significant factor in developing countries,
where sub-clinical inflammation and infection play
greater roles. There is, of course, a significant health
burden associated with preterm birth. The major risks
associated with this condition are death, respiratory-
distress syndrome, sepsis, intraventricular haemorrhage,
necrotising enterocolitis, severe neurological deficits
(including blindness and deafness) and developmental
disabilities. Studies have reported that preterm birth is
the antecedent cause of 36% of infant deaths and 50%
of neurodevelopment disabilities.21–23 Recent publi -
cations have shown that, even among late preterm
births (34 to 36 weeks), there are still significantly in -
creased rates of neonatal morbidity and mortality.24 Put
together, these findings lead to another inescapable
con sequence, namely that preterm birth is a leading
cause of health-care expenditure.
Interventions
Although preterm birth sometimes occurs as a result of
a medical decision (25%), in the majority of cases, onset
is ‘spontaneous’. Various pharmacological interventions
have been proposed and investigated based largely on
the basis of our limited understanding of the pathophy -
siology. Several plausible prophylactic (preventative)
medical interventions, such as beta-sympathomimetics,
magnesium, calcium and folate, have been shown to be
largely ineffective. Progesterone, a natural hormone
pre sent in supra-physiological levels during pregnancy,
however, has shown promise. It also makes sense to
treat conditions such as asymptomatic bacteriuria that
may predispose women to preterm labour.25 Asympto -
matic bacteriuria is particularly prevalent among low
socio-economic groups, the same groups where pre -
term labour is most problematic. Once preterm labour
has begun, tocolysis (in contrast to prophylaxis) has
enabled clinicians to delay delivery in order to accele -
rate fetal pulmonary maturation and to allow transport
to an appropriate institution for delivery. However, it is
disappointing to note that tocolysis has still not been
unequivocally associated with improved neonatal
outcome.26 Two interventions, one for the prevention
of preterm birth and one for the treatment of a specific
condition linked to preterm birth, will now be
discussed.
Progesterone for prevention of preterm birth
‘Progestin’ was first isolated from rabbit ovaries by
Allen and Corner in 1930.27 Subsequent to this im -
portant finding, the role of progesterone in the main -
tenance of mammalian pregnancies was well described.
It also became apparent that human pregnancies did not
persist after the excision of the corpus luteum (pro -
ducing progesterone) in the first half of the first tri -
mester of pregnancy.
Despite our current understanding, however, there
is still considerable speculation as to the exact mecha -
nisms whereby progesterone exerts its favoura ble in -
fluence on the maintenance of pregnancy. As far back as
1974, Csapo et al. proposed the progesterone-with -
drawal theory.28 This theory postulates that, during
preg nancy, the high ratio of progesterone to oestrogen
allows the uterus to expand but remain quiescent. At
the end of pregnancy, the role is reversed as labour
approaches and the ratio of progesterone to oestrogen
changes, allowing the cervix to ripen and the myo -
metrium to become more contractile, thus facilitating
labour. Progesterone is also known to prevent in -
flamma tion, a condition clearly linked to labour, speci -
fically preterm labour.29 Progesterone prevents the for -
mation of gap junctions and inhibits myometrial con -
tractions by down-regulating the expression of con -
traction proteins.30
Clinicians may administer progesterone in one of
two forms: natural progesterone (P) may be adminis -
tered vaginally in the form of a pessary or cream or
progesterone may be administered as 17 alpha-hydroxy
progesterone (17P), a synthetic caproate ester. When
used as prophylaxis, prolonged administration is
necessary and a less invasive intervention is therefore
preferred. Administered orally, progesterone has
variable absorption and is subject to first-pass meta -
bolism and central-nervous system sedation.31 Ad minis -
tered vaginally, the agent avoids first-pass metabolism
and achieves higher endometrial concentrations.32 This
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9route of administration is therefore preferable. 17P is
administered by injection and has been associated with
increased insulin resistance, thus posing a potential pro -
blem of gestational diabetes mellitus.
At this point, a few sentinel studies must be pre -
sented. In 2003, Meis et al. conducted a double-blind,
placebo-controlled, randomised trial among a high-risk
population with one or more previous spontaneous
pre term births.33 The active medication was 250 mg
17P, administered intramuscularly every week from 
20 weeks’ gestation. In this trial, there was a 2:1
(310:153) ratio of active to placebo oil. The primary
outcome measure was the occurrence of preterm birth
before 37 weeks’ gestation. The study showed a sig -
nificant de crease in the risk of delivery before this
gestational age (RR 0.66 [0.54 to 0.81]). The effect was
also significant at less than 35 and 32 weeks’ gestation.
However, it is important to note that 36% of the active-
ingredient group still had a preterm birth and that a
staggering 55% of the placebo group delivered early. For
this reason, prominent clinicians questioned the risk
reduction,34 while others proposed that the placebo
injections had actually increased the preterm birth
rate.35 Many ques tions thus remained unanswered.
The next significant study was also published in 2003,
by Da Fonseca et al.36 Their study population was again
a high-risk group, comprising mothers with one or more
previous spontaneous preterm births, a prophylactic
cerclage or uterine malformation. Vaginal progesterone
in the form of a 100 mg suppository was administered
daily from 24 to 34 weeks’ gestation. This was a double-
blind, placebo-controlled trial with a 1:1 ratio of active
to placebo agent (72:70), powered to show a decrease
in preterm birth from 25% to 12.5%. The results
showed that the preterm birth rate in the progesterone
group was 13.5% versus 28.5% in the placebo group.
This was a significant finding at 37, less than 37 and less
than 34 weeks (P < 0.05).
Four years later, the largest current trial investigating
progesterone for the reduction of recurrent preterm
birth was published by O’Brien et al.37 This trial was a
multi-centre, randomised, controlled trial based in
North America and included three participating South
African centres. The study population consisted of 659
women with one or more previous spontaneous pre -
term births. They self-administered vaginal proges -
terone gel (90 mg/day), starting at 18 to 22 weeks and
ending with the rupture of their membranes, delivery or
at 37 weeks’ gestation. The study was powered to show
a significant decrease in the rate of preterm birth at less
than or equal to 32 weeks’ gestation. However, the trial
did not show a significant decrease in the frequency of
preterm birth less than or equal to 32 weeks or at 35
or 37 weeks. A leading expert in the field described this
as an unexpected result.38 A sub-analysis of the patients
in this study did indicate that vaginal progesterone was
effective in preventing preterm birth in women with
ultrasonographic evidence of a short cervix in the mid-
trimester39 but the trial was not powered for this out -
come, although these findings were similar to those of
Da Fonseca et al.40 This begs the question of whether
the selection of high-risk women should combine a
history of previous preterm birth as well as a short
cervix, as measured by vaginal ultrasound.
Trans-abdominal cerclage (TAC) as a 
definitive intervention
Cervical incompetence is one of the conditions asso -
ciated with second-trimester loss and extreme preterm
delivery. Current evidence suggests that the surgical
modification of the cervix in the form of cerclage
benefits those with at least three second-trimester
losses or preterm deliveries. Patients with two early
second-trimester losses and no other identified cause
or a previous second-trimester loss and ultrasound
findings of a short cervix are also potential candidates.41
Most often, the cerclage is placed around the cervix
using the vaginal route at 12 to 14 weeks.42 When this
less invasive form of cerclage has not been successful or
when the cervix is damaged either by spontaneous
delivery or by surgical intervention, such as assisted
delivery or cone biopsy, however, the vaginal technique
may not be possible. Under these testing circumstances,
the more invasive TAC may be considered to access the
supra-vaginal portion of the cervix. Currently, there are
more than 60 pregnancies in the Stellenbosch/Tygerberg
TAC series. Up to three pregnancies have been carried
after the placement of the initial cerclage and only six
losses have occurred in this very high-risk group of
patients. When performed by an experienced surgeon
on a properly selected patient, this procedure carries
the reasonable prospect (90%) of a delivery at or close
to term, even among women for whom the goal of a
successful pregnancy seemed completely out of reach
(Table 3).
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CONCLUSIONS
Early-onset severe pre-eclampsia is not uncommonand can be a devastating complication of pregnancy.
Under carefully controlled circumstances, however,
expectant management is sufficiently safe for the
mother and provides important perinatal benefits, with
almost half of such cases qualifying for this approach.
The recommendations from the Stellenbosch/Tyger -
berg group have been widely applied. Preventing spon -
taneous preterm birth and its consequences remains a
priority that has been difficult to achieve. There is evi -
dence, however, that women with one or more pre -
term deliveries and a short cervix may benefit from
prophylactic progesterone. Finally, a damaged uterine
cervix and/or recurrent mid-trimester losses do not
preclude the chance of a successful advanced pregnancy,
which can be achieved with the aid of a TAC.
Table 3: Outcome: TAC: 60 pregnancies in 47 women
Outcome Before TAC After
TAC 
T1 miscarriage 36 0  
T2 miscarriage 73 6  
Delivery 28–33 weeks 13 7  
Delivery ≥ 34 weeks 26 47  
No living children 22 4  
Total pregnancies 148 60  
Survival at discharge 25% 90%
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